Recent news and posts
Submission of applications for subsidies under the "Early Detection" sub-program is open until March 2022
The Dutch Organization for Health Research and Development (ZonMw) works to improve disease prevention, healthcare practices, and the health status of the Dutch citizens by stimulating and funding research, development, and implementation of innovative technologies.
The "Early Detection" sub-program is part of the ZonMw prevention program. This sub-program provides subsidies for upscaling screening programs or population screening. The subsidy focuses on knowledge development on the following topics:
- Information provision and awareness to increase involvement in screening programs among specific target population groups, the interaction between population studies and awareness;
- Self-screening using innovative techniques;
- DNA self-tests among citizens;
- Advantages and disadvantages of the commercial Direct To Consumer (DTC) DNA self-tests for citizens and healthcare providers.
For small projects, a maximum subsidy of €200,000 per project with a maximum duration of 24 months can be applied for. For large projects, a maximum subsidy of €201,000-400,000 and a maximum duration of 24 to 48 months can be applied for. Co-funding from public or private sources is possible but not mandatory. Potential contributions from third parties should amount to a maximum of 50% of the total research budget.
The applications for the subsidy shall be submitted until March 8, 2022.
The full details in Dutch can be found here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).